The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Ionis Pharmaceuticals Inc shares valued at $552,862 were sold by Swayze Eric on Sep 02 ’25. At $49.67 per share, Swayze Eric sold 11,130 shares. The insider’s holdings dropped to 37,302 shares worth approximately $2.21 million following the completion of this transaction.
Also, WENDER JOSEPH H sold 16,800 shares, netting a total of over 938,606 in proceeds. Following the sale of shares at $55.87 each, the insider now holds 120,035 shares.
Before that, WENDER JOSEPH H had sold 11,200 shares from its account. In a trade valued at $673,549, the Director traded Ionis Pharmaceuticals Inc shares for $60.14 each. Upon closing the transaction, the insider’s holdings decreased to 11,200 shares, worth approximately $6.46 million.
As published in a research note from BMO Capital Markets on September 03, 2025, Ionis Pharmaceuticals Inc [IONS] has been rated up from a Market perform to an Outperform and the price target has been revised to $70. Analysts at Morgan Stanley upgraded the stock from ‘”an Equal-weight”‘ to ‘”an Overweight”‘ outlook in a report released in late July. As of July 01, 2025, Barclays has increased its “an Equal weight” rating to a “an Overweight” for IONS. Earlier on April 07, 2025, H.C. Wainwright initiated its rating. Their recommendation was “a Buy” for IONS stock.
Analyzing IONS Stock Performance
On last trading session, Ionis Pharmaceuticals Inc [NASDAQ: IONS] plunged -1.88% to $59.35. The stock’s lowest price that day was $58.845, but it reached a high of $60.75 in the same session. During the last five days, there has been a surge of approximately 38.83%. Over the course of the year, Ionis Pharmaceuticals Inc shares have jumped approximately 24.48%. Shares of the company reached a 52-week high of $62.08 on 09/03/25 and a 52-week low of $23.95 on 04/09/25.
Support And Resistance Levels for Ionis Pharmaceuticals Inc (IONS)
According to the 24-hour chart, there is a support level at 58.55, which, if violated, would cause prices to drop to 57.74. In the upper region, resistance lies at 60.45. The next price resistance is at 61.55. RSI (Relative Strength Index) is 82.00 on the 14-day chart, showing overbought technical sentiment.
Is Ionis Pharmaceuticals Inc subject to short interest?
Stocks of Ionis Pharmaceuticals Inc saw a sharp steep in short interest on 2025-08-15 dropping by -2.1 million shares to 10.79 million. Data from Yahoo Finance shows that the short interest on 2025-07-15 was 12.89 million shares. A decline of -19.51% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 5.47 of the overall float, the days-to-cover ratio (short ratio) decline to 5.47.
Which companies own the most shares of Ionis Pharmaceuticals Inc (IONS)?
In terms of Ionis Pharmaceuticals Inc share price expectations, FactSet research, analysts set an average price target of 78 in the next 12 months, up nearly 28.95% from the previous closing price of $60.49. Analysts anticipate Ionis Pharmaceuticals Inc stock to reach 96 by 2025, with the lowest price target being 43. In spite of this, 14 analysts ranked Ionis Pharmaceuticals Inc stock as Buy at the end of 2025. On March 31, 2025, Redburn Atlantic assigned a price target of “a Neutral” to the stock and initiated coverage with a $39.
